Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

759 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.
Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G, Pehrsson K, Verheugt FW, Meyer J, Betriu A, Califf RM, Li X, Fox NL; ASSENT-2 Investigators. Assessment of the Safety and Efficacy of a New Thrombolytic. Van de Werf F, et al. Eur Heart J. 2001 Dec;22(24):2253-61. doi: 10.1053/euhj.2001.2686. Eur Heart J. 2001. PMID: 11728145 Clinical Trial.
Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Van de Werf F, Califf RM, Armstrong PW, Bates ER, Ross AM, Kleinman NS, Topol EJ. Van de Werf F, et al. Eur Heart J. 1995 Aug;16(8):1024-6. doi: 10.1093/oxfordjournals.eurheartj.a061042. Eur Heart J. 1995. PMID: 8665962 No abstract available.
Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Van de Werf F, Topol EJ, Lee KL, Woodlief LH, Granger CB, Armstrong PW, Barbash GI, Hampton JR, Guerci A, Simes RJ, et al. Van de Werf F, et al. JAMA. 1995 May 24-31;273(20):1586-91. doi: 10.1001/jama.273.20.1586. JAMA. 1995. PMID: 7745771 Clinical Trial.
Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries.
Pfisterer M, Cox JL, Granger CB, Brener SJ, Naylor CD, Califf RM, van de Werf F, Stebbins AL, Lee KL, Topol EJ, Armstrong PW. Pfisterer M, et al. Among authors: van de werf f. J Am Coll Cardiol. 1998 Sep;32(3):634-40. doi: 10.1016/s0735-1097(98)00279-4. J Am Coll Cardiol. 1998. PMID: 9741504 Free article. Clinical Trial.
759 results